Atossa Signs on Third PPO for Breast Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – Atossa Genetics today said into has signed a nationwide agreement with preferred provider organization HealthSmart.

The agreement, the Seattle-based breast cancer diagnostic firm said, is to provide patients in HealthSmart's network greater access to Atossa's ForeCyte Breast Health Test. The risk stratification test for breast cancer is based on Atossa's US Food and Drug Administration-cleared Mammary Aspirate Specimen Cytology Test System, or MASCT.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: SNP reference panel from the Haplotype Reference Consortium, and more.

Halloran Consulting's Laurie Halloran lists at Stat News the mistakes she sees startup companies make when pursuing a clinical trial.

MIT researchers are using bees to collect and visualize urban microbiome samples, Wired reports.

Reliance on Excel leads to errors in gene name lists, a new Genome Biology paper reports.